Livzon Pharma Announces Updated Board and Committee Line-up

Bulletin Express
Nov 12

Livzon Pharmaceutical Group Inc. (Livzon Pharma) has released an updated roster of its Board of Directors and the corresponding committee assignments, effective 12 November 2026 from headquarters in Zhuhai, China.

The Board now comprises nine members: • Executive Directors – Chairman and President Liu Daping; Vice Chairman Tang Yanggang • Non-executive Directors – Lin Nanqi, Qiu Qingfeng, Zhu Linlin • Employee Representative Director – Ran Yongmei • Independent Non-executive Directors – Luo Huiyuan, Cui Lijie, Wang Zhiyao, Kang Li

Five board committees remain in place, with leadership and membership as follows: 1. Audit Committee: Chaired by Independent Non-executive Director Luo Huiyuan, with Kang Li, Cui Lijie, and Wang Zhiyao serving as members. 2. Remuneration and Assessment Committee: Chaired by Independent Non-executive Director Cui Lijie; Tang Yanggang, Kang Li, and Ran Yongmei are members. 3. Nomination Committee: Independent Non-executive Director Kang Li takes the chair; Tang Yanggang, Cui Lijie, and Ran Yongmei serve as members. 4. Strategy Committee: Chairman Liu Daping heads the committee, joined by Tang Yanggang and Cui Lijie as members. 5. Environmental, Social and Governance Committee: Chaired by Liu Daping, with Tang Yanggang and Kang Li as members.

These appointments reinforce Livzon Pharma’s governance framework by balancing executive leadership with independent oversight and specialized committee expertise.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10